FDA authorizes Novavax’s updated Covid vaccine, paving way for fall rollout
Publishing timestamp: 2024-08-30 15:50:23
Summary
The FDA authorized Novavax's protein-based Covid vaccine for emergency use in people ages 12 and up, targeting the omicron subvariant JN.1. The vaccine is expected to compete with Pfizer and Moderna's shots and has shown protection against other variants. Novavax's shares rose more than 8% following the announcement.
Sentiment: POSITIVE
Keywords: pfizer inc, biotech and pharmaceuticals, business, health care industry, novavax inc, science, moderna inc, breaking news: business, business news, pharmaceuticals, united states, biotechnology,
Source: https://www.cnbc.com/2024/08/30/fda-authorizes-novavax-protein-covid-vaccine.html